Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review
Human papillomavirus (HPV) causes cervical carcinoma, which and is the third most common cancer, accounting for 275,000 deaths annually worldwide. Adjuvants have a key role in promotion of vaccine efficacy; therefore, using prophylactic and therapeutic vaccines combined with adjuvant could be of great benefit in prevention and treatment of cervical cancer. There are different types of adjuvants, including MF59TM adjuvants, RNA based, JY (interleukin2/chitosan) cholera toxin (CT) heat labile enterotoxin (LT) Freund's adjuvant, alum, SA 4 1BBL, l carrageenan (l CGN) heat shock proteins (HSPs) juzen taiho to (JTT) and hochu ekki to (HET) ISCOM and ISCOMATRIX(tm) very small size proteoliposomes (VSSPs) granulocyte macrophage colony stimulating factor (GM CSF) and Toll like receptors (TLRs) Adjuvants have various functions, especially in therapeutic vaccines, and they lead to an increase in cytotoxic T lymphocytes (CTLs) so they are important in the design of vaccines. Here, we review the currently used adjuvants and their combinations with HPV protein vaccines in order to introduce an appropriate adjuvant for HPV vaccines.
Archives of Virology